Skip to main content

Immunex Subscribes to Celera Database

Premium

Celera Genomics said Immunex had purchased 5-year subscriptions to several of its genomic databases.

 

Details of the transaction were not disclosed, but earlier subscribers to Celera’s databases have reportedly paid between $25 million and $50 million for three- to five-year periods.

 

Based in Seattle, Immunex markets the arthritis drug Enbrel.

 

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.